US Drug Pricing: CMS Seeks Feedback On DTC Ad Enforcement Mechanism, Disclosure Statement
Centers for Medicare and Medicaid Services asks whether private actions under Lanham Act are sufficient for enforcement, or whether participation in federal health programs should be conditioned on including drug list prices in direct-to-consumer TV commercials; comment deadline on controversial proposed rule is Dec. 17.
You may also be interested in...
Some patient groups, payers support CMS proposal to require disclosure of list prices in TV ads but want to expand the requirement to other media and beef up enforcement. Others are skeptical the proposal would lower prices.
US may have substantial drug purchasing muscle, as evident in latest CMS proposal to reform Medicare Part B, but still needs pharma to force prices down.
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.